My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

130.77 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 315
Open 130.77
Bid (Size) 130.21 (4)
Ask (Size) 130.28 (16)
Prev. Close 130.77
Today's Range 130.77 - 130.77
52wk Range 96.06 - 133.55
Shares Outstanding N/A
Dividend Yield 3.05%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AI: The Medical Maverick – Navigating Hype and Hope in Healthcare’s Digital Revolution
Artificial intelligence (AI) stands at the precipice of a profound transformation in healthcare, promising a future where diagnostics are sharper, treatments are more personalized, and patient care is... 
Via TokenRing AI
Topics Artificial Intelligence
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity
William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therapy pipeline. 
Via Benzinga

Performance

YTD
+34.6%
+34.6%
1 Month
+6.5%
+6.5%
3 Month
+14.2%
+14.2%
6 Month
+18.0%
+18.0%
1 Year
+12.2%
+12.2%

More News

Read More
Novartis Strengthens Kidney Disease Pipeline With Promising Data
Via Benzinga
Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Case for Value Investors
Via Chartmill
Vor Bio's Collaborator Delivers Positive Results For Telitacicept In Autoimmune Disorder That Impacts Tears
Via Benzinga
Cogent Biosciences Soars to 52-Week High on "Breakthrough" Systemic Mastocytosis Trial Results
Via MarketMinute
Topics Economy Supply Chain
Drug Stocks Just Had Their Best Week in 2 Decades. Should You Invest?
Via The Motley Fool
Topics ETFs Government World Trade
JPMorgan Elevates Incyte Price Target Amidst Robust Pipeline and Commercial Success, Yet Maintains Cautious "Neutral" Stance
Via MarketMinute
Topics Economy Intellectual Property
Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook
Via MarketMinute
Cullen Capital Dumps 40% of BCE Holdings
Via The Motley Fool
AI Unlocks Secrets of Intrinsically Disordered Proteins: A Paradigm Shift in Biomedical Design
Via TokenRing AI
Topics Artificial Intelligence Derivatives
European Markets Soar: Healthcare and Mining Lead the Charge Amidst Dovish Fed and Robust Fundamentals
Via MarketMinute
Topics Artificial Intelligence Economy Electric Vehicles
2 Surefire Dividend Stocks to Buy for the Long Haul
Via The Motley Fool
Topics Economy Government Intellectual Property
Decoding Life's Blueprint: New Tech Maps RNA-Protein Interactions, Unlocking Disease Cures
Via MarketMinute
Topics Artificial Intelligence Derivatives
Amgen Surges on Repatha Expansion, Manufacturing Boost, and Strong Earnings
Via MarketMinute
Topics Economy Intellectual Property Stocks
Generative AI Unleashes a New Era in Genome Editing, Outperforming Nature in Protein Design
Via TokenRing AI
Topics Artificial Intelligence
AI Revolutionizes Pharma: Market Soars Towards $65 Billion by 2033, Promising a New Era of Medicine
Via TokenRing AI
Topics Artificial Intelligence Economy
Cullen Trims KVUE Stake With $149.5M Share Sale
Via The Motley Fool
Topics Regulatory Compliance
Healthcare Sector Navigates Turbulent Waters as Drug Pricing Agreements Reshape Market Landscape
Via MarketMinute
Topics Artificial Intelligence Economy Government
Cullen Sells 1.4 Million Dow Shares Worth $39.7 Million Amid Steep Stock Decline
Via The Motley Fool
Topics Stocks
Pharma's Direct-To-Patient Wave Hits Novartis Next
Via Benzinga
Digital Pharma Advances 2026: AI and Patient-Centric Strategies Transform Pharma Marketing
Via PRLog
Topics Artificial Intelligence
AstraZeneca's Strategic Listing Harmonization: A Unified Global Platform for Growth
Via MarketMinute
Topics Economy
Novartis AG-Sponsored ADR (NYSE:NVS): A Strong Dividend Stock with High Profitability and Sound Financial Health
Via Chartmill
Major Insider Sale Casts Shadow on LENZ Therapeutics' Valuation
Via MarketMinute
Topics Artificial Intelligence

Frequently Asked Questions

Is Novartis AG Common Stock publicly traded?
Yes, Novartis AG Common Stock is publicly traded.
What exchange does Novartis AG Common Stock trade on?
Novartis AG Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novartis AG Common Stock?
The ticker symbol for Novartis AG Common Stock is NVS on the New York Stock Exchange
What is the current price of Novartis AG Common Stock?
The current price of Novartis AG Common Stock is 130.77
When was Novartis AG Common Stock last traded?
The last trade of Novartis AG Common Stock was at 10/16/25 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.